Clinical Evaluation of Pramipexole in Advanced Parkinson's Disease
Neurol 49:162-168, Lieberman,A.,et al, 1997
Efficacy of Pramipexole, A Novel Dopamine Agonist, As Monotherapy in Mild to Moderate Parkinson's Disease
Neurol 49:724-728, Shannon,K.M.,et al, 1997
Pharmacologic Profile of Ropinirole:A Nonergoline Dopamine Agonist
Neurol 49:558-562, Tulloch,I.F., 1997
Ropinirole for the Treatment of Early Parkinson's Disease
Neurol 49:393-399, Adler,C.H.,et al, 1997
Cabergoline Treatment of Early Parkinson's Disease:First Yr of Trtm Comparison of Cabergoline & Levodopa
Neurol 48:363-368, Rinne,U.K.,et al, 1997
Reversible MRI Findings in a Patient with Hashimoto's Encephalopathy
Neurol 49:246-247, Bohnen,N.I.L.J.,et al, 1997
Excess Glutamate Levels in the Cerebrospinal Fluid Predict Clinical Outcome of Bacterial Meningitis
Arch Neurol 53:992-996, Spranger,M.,et al, 1996
Chiasmal Herniation as a Complication of Bromocriptine Therapy
J Neuro-Ophthalmol 16:252-257, Taxel,P.,et al, 1996
Multicenter, Placebo-Controlled Trial of Cabergoline Taken Once Daily in the Treatment of Parkinson's Disease
Neurol 46:1062-1065, Hutton,J.T.,et al, 1996
Double-Blind Comparison of Cabergoline & Bromocriptine in Parkinson's Disease Pts with Motor Fluctuations
Neurol 47:785-788, Inzelberg,R.,et al, 1996
Restless Legs Syndrome:Clinicoetiologic Correlates
Neurol 47:1435-1441, Ondo,W.&Jankovic,J., 1996
Dose-Ranging Study of Riluzole in Amyotrophic Lateral Sclerosis
Lancet 347:1425-1431, Lacomblez,L.,et al, 1996
From Enigmatic to Problematic:The New Molecular Genetics of Childhood Spinal Muscular Atrophy
Neurol 46:335-340, Crawford,T.O., 1996
Bromocriptine and Postpartum Cerebral Angiopathy:A Causal Relationship
Neurol 46:1754-1756, Comabella,M.,et al, 1996
A Woman with a Relapsing Psychosis Who Got Better with Prednisone
Lancet 347:1288, Cohen,L.,et al, 1996
Paraneoplastic Limbic Encephalitis in Hodgkin's Disease
Can J Neurol Sci 23:138-140, Deodhare,S.,et al, 1996
Retroperitoneal Fibrosis in a Patient with Parkinson's Disease Treated with Pergolide
Clin NeuroPharmacol 18:277-279, Jimenez-Jimenez,F.J.,et al, 1995
Myasthenic Symptoms in Patients with Mitochondrial Myopathies
Muscle & Nerve 18:1338-1340995., Forestier,N.L.,et al, 1995
Acetylcholine Receptor Antibodies in Patients with Graves'Ophthalmopathy
J Neuro-Ophthalmol 15:166-170, Jacobson,D.M., 1995
Complementary Positron Emission Tomographic Studies of the Striatal Dopaminergic System in Parkinson's Disease
Arch Neurol 52:1183-1190, Antonini,A.,et al, 1995
Increased Incidence of Levodopa Therapy Following Metoclopramide Use
JAMA 274:1780-1782, Avorn,J.,et al, 1995
Postpartum Cerebral Angiopathy Possibly Due to Bromocriptine Therapy
Stroke 26:128-130, Janssens,E.,et al, 1995
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
The Poisoned Patient with Altered Consciousness, Controversies in the Use of a"Coma Cocktail"
JAMA 274:562-569, Hoffman,R.S.&Goldfrank,L.R., 1995
Levorotatory Form of 5-Hydroxytryptophan in Friedreich's Ataxia
Arch Neurol 52:456-460, Trouillas,P.,et al, 1995
Double-Blind Study with Levorotatory form of Hydroxytryptophan in Pts with Degen Cerebellar Dis
Arch Neurol 52:451-455, 4401995., Wessel,K.,et al, 1995
Electroencephalographic Findings in Hashimoto's Encephalopathy
Neurol 45:977-981, Henchey,R.,et al, 1995
Myasthenia Gravis During Interferon Alfa Therapy
Neurol 45:382-383, Batocchi,A.P.,et al, 1995
Diagnosis and Management of Pituitary Tumours
BMJ 308:1087-1091, Levy,A.&Lightman,S.L., 1994
Paraneoplastic Temporal Lobe Epilepsy with Testicular Neoplasm and Atypical Amnesia
neurol 44:1270-1274, Ahern,G.L.,et al, 1994
A Multicenter Double-Blind Placebo-Controlled Trial of Pergolide as an Adjunct to Sinemet in Parkinson's Disease
Movement Disorders, 9:40-471994., Olanow,C.W.,et al, 1994
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Phenytoin and Ranitidine Interaction
Ann Int Med 120:892-893, Tse,C.S.T.&Iagmin,P., 1994
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Fluctuating Parkinson's Disease:Treatment with the Long-Acting Dopamine Agonist Cabergoline
Arch Neurol 51:1236-1241, Ahlskog,J.E.,et al, 1994
Oral and Genital Tardive Pain Syndromes
Neurol 44:2115-2119, Ford,B.,et al, 1994
Reverse Shapiro's Syndrome:Hirayama
K. , et al, Arch Neurol 51:494-49694., , 1994
Treatment with D-penicillamine Improves Dopamine D2-Receptor Binding and T2-Signal Intensity in de novo Wilson's Disease
Neurol 44:1079-1082, Schwarz,J.,et al, 1994
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Congenital Myasthenic Syndromes
In:Neurologic Clinics, 12:401-4371994., Engel,A.G., 1994
Race, Sex, and Puberty Influence Onset, Severity, and Outcome in Juvenile Myasthenia Gravis
Neurol 44:1208-1214, Andrews,P.I.,et al, 1994
Reversible Paraneoplastic Limbic Encephalitis
Neurol 43:2418-2419, Kaniecki,R.&Morris,J.C., 1993
Cabergoline in Parkinson's Disease:Long-Term Follow-up
Neurol 43:2587-2590, Lera,G.,et al, 1993
Multictr Study of Cabergoline, A Long-Acting Dopamine Receptor Agonist, in PD Fluct Resp to Levodopa/Carbidopa
Neurol 43:1981-1984, Lieberman,A.,et al, 1993
Schizophrenia as a Brain Disease, The Dopamine Receptor Story
Arch Neurol 50:1093-1095, 10971993., Seeman,P., 1993
Schizophrenia as a Brain Disease
Arch Neurol 50:1096-1097, Williamson,P.C., 1993
Total Body Irradiation for Myasthenia Gravis:A Long-Term Follow-up
Neurol 43:2215-2221, Durelli,L.,et al, 1993
Prolactin-Secreting Macroadenomas in Adolescents, Response to Bromocriptine Therapy
Am J Dis Child 147:1057-1061, Tyson,D.,et al, 1993
Acromegaly:Treatment After 100 Years
BMJ 307:1505-1506, Wass,J.A.H., 1993
Cell Culture Evidence for Neuronal Degeneration in ALS to Glutamate AMPA/Kainate Receptors
Lancet 341:265-268, Couratier,P.,et al, 1993